Moody’s affirms Cigna Group’s Baa1 debt rating, outlook stable

Published 24/10/2025, 18:30
© Reuters.

Investing.com -- Moody’s Ratings has affirmed The Cigna Group’s senior unsecured debt rating at Baa1, maintaining a stable outlook for the health services company and its subsidiaries.

The rating agency also affirmed Cigna Holding Company’s senior unsecured debt rating at Baa1, Cigna’s preferred shelf at (P)Baa3, and senior unsecured shelf at (P)Baa1.

Additionally, Moody’s affirmed the A2 insurance financial strength ratings of Connecticut General Life Insurance Company and Cigna Health & Life Insurance Company, along with Cigna’s P-2 commercial paper rating.

The affirmation reflects Cigna’s strong market position in the commercial space and relatively low underwriting risk due to its high percentage of administrative services only (ASO) business. Moody’s also cited the company’s strong risk-based capital position and diversification through its Evernorth health services unit, which generates more than half of cash flows to the parent.

These strengths are partially offset by Cigna’s relatively high leverage for its rating category, though it has remained steady. As of June 30, 2025, the company’s debt/EBITDA with Moody’s adjustments was 2.5x compared to 2.6x the prior year, while debt/capital with Moody’s adjustments was 44.5% compared to 43.8% as of June 30, 2024.

Moody’s noted that Cigna’s insurance business is mostly concentrated in the commercial insurance segment following the sale of its Medicare business in March. While the commercial market has been adversely impacted by higher medical cost trends, this focus has allowed Cigna to avoid the more significant earnings pressures seen in Medicare and Medicaid segments.

The stable outlook is based on Cigna’s steady performance, reflecting its lower-risk ASO business and diversification from Evernorth health services. Moody’s expects Cigna to continue competing effectively in commercial insurance and traditional pharmacy services while generating growth in specialty pharmacy and care services.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.